Charmacy Pharmaceutical 미래 성장
Future 기준 확인 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Charmacy Pharmaceutical.
주요 정보
n/a
수익 성장률
n/a
EPS 성장률
Healthcare 수익 성장 | 22.1% |
매출 성장률 | n/a |
향후 자기자본 수익률 | n/a |
애널리스트 커버리지 | None |
마지막 업데이트 | n/a |
최근 미래 성장 업데이트
Recent updates
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased
May 13There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump
Apr 24Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 19These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well
Oct 25If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity
Sep 17Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?
May 02What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Mar 15Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?
Feb 17We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide
Jan 27Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture
Jan 09What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us
Dec 22Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years
Nov 29이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Charmacy Pharmaceutical 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.
SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.
수익 및 매출 성장 예측
날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
---|---|---|---|---|---|
6/30/2024 | 4,482 | 52 | -63 | -42 | N/A |
3/31/2024 | 4,443 | 52 | -100 | -69 | N/A |
12/31/2023 | 4,404 | 51 | -137 | -97 | N/A |
9/30/2023 | 4,480 | 74 | -163 | -125 | N/A |
6/30/2023 | 4,557 | 96 | -190 | -153 | N/A |
3/31/2023 | 4,366 | 93 | -77 | -55 | N/A |
12/31/2022 | 4,175 | 90 | 35 | 44 | N/A |
9/30/2022 | 3,931 | 54 | 44 | 51 | N/A |
6/30/2022 | 3,688 | 18 | 53 | 59 | N/A |
3/31/2022 | 3,741 | 20 | 4 | 20 | N/A |
12/31/2021 | 3,794 | 23 | -45 | -20 | N/A |
9/30/2021 | 3,959 | 29 | 75 | 111 | N/A |
6/30/2021 | 4,124 | 36 | 195 | 241 | N/A |
3/31/2021 | 4,058 | 38 | 137 | 186 | N/A |
12/31/2020 | 3,992 | 41 | 79 | 131 | N/A |
9/30/2020 | 3,819 | 35 | -100 | -37 | N/A |
6/30/2020 | 3,645 | 29 | -280 | -205 | N/A |
3/31/2020 | 3,569 | 34 | -175 | -101 | N/A |
12/31/2019 | 3,493 | 40 | -70 | 4 | N/A |
9/30/2019 | 3,557 | 41 | -31 | 44 | N/A |
6/30/2019 | 3,621 | 42 | 7 | 84 | N/A |
3/31/2019 | 3,778 | 44 | -21 | 66 | N/A |
12/31/2018 | 3,935 | 45 | -49 | 49 | N/A |
9/30/2018 | 4,075 | 46 | -122 | 6 | N/A |
6/30/2018 | 4,214 | 47 | -196 | -37 | N/A |
3/31/2018 | 4,155 | 46 | N/A | -35 | N/A |
12/31/2017 | 4,096 | 45 | N/A | -33 | N/A |
9/30/2017 | 3,946 | 54 | N/A | -82 | N/A |
6/30/2017 | 3,796 | 63 | N/A | -130 | N/A |
3/31/2017 | 3,733 | 60 | N/A | -116 | N/A |
12/31/2016 | 3,670 | 56 | N/A | -102 | N/A |
9/30/2016 | 3,605 | 47 | N/A | -27 | N/A |
6/30/2016 | 3,540 | 38 | N/A | 47 | N/A |
3/31/2016 | 3,468 | 32 | N/A | 120 | N/A |
12/31/2015 | 3,397 | 26 | N/A | 194 | N/A |
9/30/2015 | 3,299 | 31 | N/A | 156 | N/A |
6/30/2015 | 3,200 | 35 | N/A | 119 | N/A |
3/31/2015 | 3,107 | 36 | N/A | 52 | N/A |
12/31/2014 | 3,014 | 36 | N/A | -15 | N/A |
12/31/2013 | 2,401 | 22 | N/A | 45 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: Insufficient data to determine if 2289's forecast earnings growth is above the savings rate (2.3%).
수익 vs 시장: Insufficient data to determine if 2289's earnings are forecast to grow faster than the Hong Kong market
고성장 수익: Insufficient data to determine if 2289's earnings are expected to grow significantly over the next 3 years.
수익 대 시장: Insufficient data to determine if 2289's revenue is forecast to grow faster than the Hong Kong market.
고성장 수익: Insufficient data to determine if 2289's revenue is forecast to grow faster than 20% per year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: Insufficient data to determine if 2289's Return on Equity is forecast to be high in 3 years time